Salvage chemotherapy using gemcitabine for taxane/platinum-resistant recurrent ovarian cancer: a single institutional experience.

@article{Yoshino2012SalvageCU,
  title={Salvage chemotherapy using gemcitabine for taxane/platinum-resistant recurrent ovarian cancer: a single institutional experience.},
  author={Kiyoshi Yoshino and Kosuke Hiramatsu and Takayuki Enomoto and Masami Fujita and Yutaka Ueda and Toshihiro Kimura and Eiji Kobayashi and Yumiko Kiyohara and Tateki Tsutsui and Tadashi Kimura},
  journal={Anticancer research},
  year={2012},
  volume={32 9},
  pages={4029-33}
}
BACKGROUND The purpose of this study was to report on the safety and efficacy of gemcitabine used as salvage chemotherapy for ovarian cancer. PATIENTS AND METHODS From January 2002 to October 2011, 27 patients were treated with gemcitabine for platinum-resistant recurrent ovarian cancer. Gemcitabine (800 mg/m(2)) was given on days 1, 8, and 15 of every 28 days. The patients' medical records were retrospectively reviewed. RESULTS All 27 patients had previously received paclitaxel/carboplatin… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 19 references

Similar Papers

Loading similar papers…